XML 74 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Share-Based Payments - 2017 Share Incentive Plan (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Jul. 26, 2017
shares
Dec. 31, 2018
USD ($)
item
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Additional disclosures        
Share-based compensation expense | $   $ 5,154 $ 5,732 $ 2,545
2017 Share Incentive Plan        
Weighted average exercise price in $ per share        
Outstanding balance at beginning of year (in dollars per share) | $ / shares   $ 6.92 $ 0.00  
Granted (in dollars per share) | $ / shares   5.27 6.92  
Forfeited (in dollars per share) | $ / shares   6.75    
Outstanding balance at end of year (in dollars per share) | $ / shares   5.41 $ 6.92 $ 0.00
Vested and exercisable balance at end of year (in dollars per share) | $ / shares   $ 6.88    
Options        
Outstanding at beginning of year (in shares)   294,100 0  
Granted (in shares)   2,199,225 294,100  
Exercised (in shares)   0 0  
Forfeited (in shares)   (94,900)    
Outstanding at end of year (in shares)   2,398,425 294,100 0
Vested and exercisable at end of year (in shares)   119,287    
2017 Share Incentive Plan | $1.46 per share to $8.35 per share        
Additional disclosures        
Options outstanding (in shares)   2,398,425    
Exercise price minimum range | $ / shares   $ 1.46    
Exercise price maximum range | $ / shares   $ 8.35    
Weighted average remaining contractual life   9 years 3 months 18 days    
2017 Share Incentive Plan | Ordinary Shares        
Share-Based Payments        
Number of shares authorized 3,000,000      
Additional shares authorized 3,438,990      
Shares available for grant   5,064,378    
2017 Share Incentive Plan | Ordinary Shares | Minimum        
Share-Based Payments        
Annual increase, to be added on the first day of each fiscal year (in shares) 2,000,000      
Annual increase, to be added on the first day of each fiscal year (as a percent) 4.00%      
2017 Share Incentive Plan | Stock Options        
Share-Based Payments        
Exercise period   10 years    
Fair Value Assumptions        
Expected term of options (in years)   6 years 1 month 6 days 6 years  
Dividend yield (as a percent)   0.00% 0.00%  
Additional disclosures        
Share-based compensation expense | $   $ 1,800 $ 100  
Weighted-average grant date fair value (in dollars per share) | $ / shares   $ 3.06 $ 3.98  
Total unrecognized compensation related to unvested options | $   $ 5,700    
Recognition period   3 years 1 month 6 days    
2017 Share Incentive Plan | Stock Options | Minimum        
Fair Value Assumptions        
Expected volatility (as a percent)   59.80% 59.50%  
Risk-free interest rate (as a percent)   2.55% 1.93%  
Additional disclosures        
Term of U.S. treasury securities used to estimate risk free interest rate   5 years    
2017 Share Incentive Plan | Stock Options | Maximum        
Fair Value Assumptions        
Expected volatility (as a percent)   61.40% 63.00%  
Risk-free interest rate (as a percent)   3.03% 2.27%  
Additional disclosures        
Term of U.S. treasury securities used to estimate risk free interest rate   7 years    
2017 Share Incentive Plan | SARs        
Share-Based Payments        
Exercise period   10 years    
2017 Share Incentive Plan | Restricted Stock Units ("RSUs")        
Additional disclosures        
Share-based compensation expense | $   $ 0    
Restricted Stock Units        
Restricted stock granted during the period   407,150    
Weighted average grant date fair value per share | $ / shares   $ 5.82    
Number of shares outstanding   387,800    
Expiration period if drug is not approved   2 years    
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Employees        
Additional disclosures        
Share-based compensation expense | $   $ 200    
Restricted Stock Units        
Restricted stock granted during the period   834,300    
Weighted average grant date fair value per share | $ / shares   $ 2.16    
Number of shares outstanding   834,300    
Number of vesting periods | item   3    
Vesting period   6 months    
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Immediate vesting upon regulatory approval        
Restricted Stock Units        
Percentage that vests during the period   50.00%    
2017 Share Incentive Plan | Restricted Stock Units ("RSUs") | Vesting upon the one-year-anniversary of FDA approval        
Restricted Stock Units        
Percentage that vests during the period   50.00%    
Vesting period   1 year